Published on July 31st, 20190
Many of these unapproved drug treatment claims were made in blogs with titles like “CBD Benefits: Top 5 Research-Backed Benefits of CBD” that Curaleaf told the Boston Globe have been deleted in the wake of the agency’s July 22 letter. (A screenshot of the company’s hemp website taken in early May shows a “blog” tab that, as of this writing, isn’t currently found on the site.)
Curaleaf also told the Globe that it removed the social media posts in question and that “a number of the products mentioned in the FDA letter had previously been discontinued,” including a vape pen. The letter also mentioned a lotion, which is still available for purchase on the site, a “pain-relief patch” and a CBD oil for pets.
Curaleaf, which boasts that it’s “the leading vertically integrated cannabis operator” in the country, said in a statement that it “will work collaboratively with the FDA to resolve all issues addressed in the agency’s letter.”
Click here for more of our coverage on the FDA’s efforts to rein in the deceptive marketing of CBD, which is the compound in cannabis that, unlike THC, does not cause a high and has been promoted as a treatment for, well, you name it.
Only drugs can be marketed as having the ability to diagnose, cure, treat, prevent or mitigate a disease, and the only way for a product to gain legit drug status is by getting FDA approval, which means any product that doesn’t get FDA approval can’t say it has the ability to diagnose, cure, treat, prevent or mitigate a disease.